Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 434 of 5804
-
Head-to-Head: which drug tames ulcerative colitis better?
Disease control OngoingUlcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and effective risankizumab is compared to vedolizumab in treating adult participants w…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could a platelet-boosting drug improve blood counts in certain blood cancers?
Disease control TerminatedThe purpose of this study is to evaluate if a study drug called eltrombopag can improve the blood cell counts in patients with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) with mutations in TET2 gene, observe changes in the TET2 gene over ti…
Phase: PHASE2 • Sponsor: Abhay Singh, MD MPH • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New immunotherapy combo aims to tackle tough lung cancer
Disease control OngoingThis study is a multicenter, open label phase I clinical trial aimed at evaluating the pharmacokinetics, tolerability, safety and immunogenicity of SHR-1316 (sc) subcutaneous administration combined with carboplatin and etoposide as first-line treatment for extensive stage small …
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill shows promise for severe postpartum depression in phase 3 trial
Symptom relief CompletedThe purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what sid…
Phase: PHASE3 • Sponsor: Lipocine Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Off-the-Shelf immune cells take on tough blood cancers
Disease control Recruiting nowThis study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \</= 10% blast following prio…
Phase: PHASE1 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Gene therapy injection into the brain aims to treat rare genetic disorder
Disease control OngoingThis is a first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of RB001 administered via intracerebroventricular (ICV) injection in pediatric with SHANK3 related Phelan-McDermid Syndrome. Clinical data will…
Phase: PHASE1 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Gene therapy breakthrough for rare kidney disease enters human trials
Disease control Recruiting nowThe goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In …
Phase: PHASE1, PHASE2 • Sponsor: Arbor Biotechnologies • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New program aims to help men with HIV in fishing communities cut alcohol and boost treatment success
Disease control Recruiting nowThe investigators developed the Kisoboka ("It is possible") Intervention to address limitations of existing evidence-based interventions to optimize treatment as prevention among men living with HIV who drink alcohol at hazardous levels in "risk environments" such as fishing comm…
Phase: NA • Sponsor: San Diego State University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could combining malaria vaccine with seasonal prevention save more kids?
Prevention Recruiting nowThis is a two-arm, cluster-randomised, phase IV trial conducted in Chad to assess the protective efficacy and impact in real-life conditions of a new strategy for administering the R21/MM malaria vaccine, synchronized within a seasonal malaria chemoprevention (SMC) campaign, amon…
Phase: PHASE4 • Sponsor: Epicentre • Aim: Prevention
Last updated Jun 27, 2026 12:07 UTC
-
Could a common stroke drug speed up brain bleed recovery?
Disease control Recruiting nowIntracerebral hemorrhage (ICH) is a dangerous form of stroke with high mortality rate. Other than evacuating the hematoma with surgical procedures, there is no current effective internal medicine treatment. Currently, there are many novel internal medicine treatment under develop…
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on tough ovarian cancer in first human trial
Disease control Recruiting nowThe goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time tre…
Phase: PHASE1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
88% of patients with asthma and nasal polyps achieve dual remission on dupilumab
Disease control CompletedBackground: "Remission" is a primary therapeutic goal in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), though definitions vary regarding olfactory function. We evaluated "Dual Remission" kinetics in patients treated with dupilumab over 24 months. Methods: T…
Sponsor: Azienda Ulss 2 Marca Trevigiana • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can the right dose and timing of steroids save more lives in ARDS?
Disease control Recruiting nowThe early phase of Acute Respiratory Distress Syndrome (ARDS) is characterized by intense alveolar inflammation. Corticosteroids have been used to treat ARDS for decades. Although their efficacy has been a subject of ongoing controversy, recent clinical practice guidelines for AR…
Phase: PHASE4 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New device sucks blood clots from lungs in acute PE trial
Disease control Recruiting nowTo evaluate the efficacy, safety, and long-term functional outcomes of percutaneous mechanical aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for the treatment of acute pulmonary embolism.
Phase: NA • Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a wearable sensor replace fingerstick tests in the ICU?
Disease control CompletedHigh blood glucose levels (hyperglycaemia) are very common in patients admitted to intensive care units (ICUs) and are associated with worse health outcomes. Traditionally, glucose levels in critically ill patients are monitored using point-of-care blood glucose (POC-G) testing (…
Phase: NA • Sponsor: Institut d'Investigacions Biomèdiques August Pi i Sunyer • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a single infusion of 'Peacekeeper' cells let kidney transplant patients ditch most of their meds?
Disease control Recruiting nowThe goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients. Enrolled subjects will b…
Phase: PHASE2 • Sponsor: Singulera Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose select…
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug KarXT aims to tame bipolar mania in major trial
Symptom relief Recruiting nowThis is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to evaluate the efficacy of KarXT compar…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
CBD shows promise in opioid recovery: major trial underway
Disease control Recruiting nowThe long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD). The first phase of this project was an open cross-over design study in healthy individuals to confirm the safety and pharmacok…
Phase: PHASE3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Brain zaps could predict who gets relief from stubborn depression
Symptom relief ENROLLING_BY_INVITATIONThe primary aim of the study is to find the combination of neuroimaging-related markers, demographics, and clinical characteristics that predict the response of patients with therapy-resistant depression to theta-burst rTMS treatment. The secondary aim is to monitor the cognitive…
Phase: NA • Sponsor: Semmelweis University • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC